Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Medical Background<br />
Deep vein thrombosis (DVT) occurs when a blood<br />
clot develops in the deep veins of the legs. A blood<br />
clot in the deep veins poses the risk of detaching<br />
from the vessel wall and migrating towards the<br />
heart and entering the lungs. If the embolus gets<br />
lodged in a pulmonary artery or one of its branches,<br />
it can interrupt further blood fl ow and cut off<br />
oxygen supply to the body, leading to a life-threatening<br />
condition known as pulmonary embolism.<br />
DVT/PE is often associated with<br />
- Long periods of immobility<br />
- Cancer<br />
- Hypercoagulation, as a result of hereditary factors<br />
or illness<br />
- Abdominal or orthopedic (knee, hip replacement)<br />
surgeries.<br />
<strong>Aventis</strong> approaches to treat thrombosis<br />
Thrombus<br />
formation<br />
Direct Factor Xa<br />
inhibitors<br />
0673<br />
Direct<br />
thrombin<br />
inhibitors<br />
Thrombolysis<br />
Blood<br />
coagulation<br />
Activation<br />
of coagulation<br />
Factor Xa<br />
Factor IIa<br />
(Thrombin)<br />
via AT III<br />
via AT III<br />
via AT III<br />
Indirect<br />
Factor Xa<br />
inhibitors<br />
Heparin:<br />
Lovenox<br />
Fibrin<br />
Activation of<br />
plasminogen<br />
>> 30
Change language